Skip to main navigation
Vaxcyte
  • Mission
  • Pipeline
  • Approach
  • About Us
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financials & Filings
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Tax Disclosures
  • Careers
Select Page
  • RSS Feeds
  • Email Alerts
  • IR Contact

Press Releases

Sep 19, 2023

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 08, 2023

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 11, 2023

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

Jul 06, 2023

Vaxcyte Mourns the Sudden Passing of Board Member and Biopharmaceutical Industry Leader Michael Kamarck, Ph.D.

Jun 01, 2023

Vaxcyte to Present at the Jefferies Healthcare Conference

May 08, 2023

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

May 03, 2023

Vaxcyte to Present at the BofA Securities 2023 Health Care Conference

Apr 21, 2023

Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 19, 2023

Vaxcyte Announces Pricing of $500 Million Public Offering

Apr 17, 2023

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 18
Vaxcyte

ABOUT US

  • Corporate Profile
  • Management Team
  • Board of Directors
  • Scientific Advisory Board

OUR PROGRAMS

  • High-Fidelity Vaccines Engineered to Go the Distance
  • The Rising Consequences of Bacterial Infections
  • Vaccine Candidates Engineered to Overtake Convention
  • Posters / Publications

INVESTORS & MEDIA

  • Overview
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Investor Resources
© 2023 Vaxcyte, Inc.
© 2023 Vaxcyte, Inc.